Adjuvant chemoradiotherapy vs chemotherapy after R0 D2 gastrectomy for gastric cancer: Meta-analysis of randomized trials

Table 2 Summary of quantitative syntheses

Analysis	k /n	Effect	Modified KH 95%CI	I²	GRADE	Interpretation
DFS/RFS, all eras	7/2256	HR = 0.82	0.69-0.98	0%	Low	Point estimate favors CRT; indirect legacy evidence
DFS/RFS, oral fluoropyrimidine–platinum doublets	4/1754	HR = 0.88	0.66-1.18	0%	Moderate	Imprecise; benefit and harm remain possible
DFS/RFS, excluding Kwon et al[15] and Kim et al[16] reconstructions	5/2105	HR = 0.84	0.68-1.03	0%	Low	Conservative CI crosses no effect
Overall survival	5/1580	HR = 0.89	0.69-1.15	0%	Low	Imprecise; no equivalence inference
Locoregional recurrence, legacy	4/960	OR = 0.50	0.26-0.94	0%	Low	Improved local control; uncertain current relevance
Distant recurrence, legacy	4/960	OR = 0.81	0.50-1.29	0%	Low	Uncertain effect

n is the sum of participants represented by the selected outcome comparisons rather than a uniform randomized denominator. Grading of Recommendations Assessment, Development and Evaluation categories are the final author-reviewed certainty ratings for the evidence bodies shown in Table 2; detailed downgrade reasons and sensitivity-analysis membership are supplied in the audit workbook. CI: Confidence interval; CRT: Chemoradiotherapy; GRADE: Grading of Recommendations Assessment, Development and Evaluation; HR: Hazard ratio; OR: Odds ratio; DFS: Disease-free survival; RFS: Recurrence-free survival.